|
Gambacorti-Passerini, C; Hank, J A; Albertini, M R et al. (1993) A pilot phase II trial of continuous-infusion interleukin-2 followed by lymphokine-activated killer cell therapy and bolus-infusion interleukin-2 in renal cancer. J Immunother Emphasis Tumor Immunol 13:43-8
|
|
Albertini, M R; Howard, S P; Fisch, P et al. (1993) Modulation of target-cell culture conditions alters susceptibility to lymphocyte-mediated lysis. J Immunother Emphasis Tumor Immunol 13:243-51
|
|
Albertini, M R; Hank, J A; Sondel, P M (1992) Strategies for improving antitumor activity utilizing IL-2: preclinical models and analysis of antitumor activity of lymphocytes from patients receiving IL-2. Biotherapy 4:189-98
|
|
Albertini, M R; Gibson, D F; Robinson, S P et al. (1992) Influence of estradiol and tamoxifen on susceptibility of human breast cancer cell lines to lysis by lymphokine-activated killer cells. J Immunother (1991) 11:30-9
|
|
Albertini, M R; Nicklas, J A; Chastenay, B F et al. (1991) Analysis of T cell receptor beta and gamma genes from peripheral blood, regional lymph node and tumor-infiltrating lymphocyte clones from melanoma patients. Cancer Immunol Immunother 32:325-30
|
|
Gambacorti-Passerini, C; Hank, J A; Borchert, A et al. (1991) In vivo effects of multiple cycles of recombinant interleukin-2 (IL2) on peripheral granulocyte-macrophage hematopoietic progenitors circulating in the blood of cancer patients. Tumori 77:420-2
|
|
Albertini, M R; Oettel, K R; Weil-Hillman, G et al. (1990) Limiting dilution analysis of lymphokine-activated killer cell precursor frequencies in peripheral blood lymphocytes of cancer patients receiving interleukin-2 therapy. J Biol Response Mod 9:456-62
|
|
Albertini, M R; Sosman, J A; Hank, J A et al. (1990) The influence of autologous lymphokine-activated killer cell infusions on the toxicity and antitumor effect of repetitive cycles of interleukin-2. Cancer 66:2457-64
|
|
Gambacorti-Passerini, C; Sondel, P M (1990) Problems, controversies, and perspectives on the clinical use of interleukin-2. Curr Opin Oncol 2:1139-45
|
